AB Science has a unique and diversified indication portfolio that includes multiple late-stage programs.

Compound

Therapeutic area

Indication

Preclinical

Phase 1

Phase 2

Phase 2B/3

Confirmatory Phase 3

NDA/MAA

Pipeline AB Science October 2021

* Positive Phase 2B/3 Results Reported